Research Article
Long-Term GAD-alum Treatment Effect on Different T-Cell Subpopulations in Healthy Children Positive for Multiple Beta Cell Autoantibodies
Table 1
Baseline characteristics.
| | GAD-alum
| Placebo
|
| | Gender, (%) | | | | Female | 7 (53.8) | 4 (30.8) | | Male | 6 (46.2) | 9 (69.2) | | First degree relatives, (%) | | | | Yes | 4 (30.8) | 2 (15.4) | | No | 9 (69.2) | 11 (84.6) | | High risk HLA haplotypes, (%) | | | | DR3-DQ2 | 5 (38.4) | 7 (53.8) | | DR4-DQ8 | 13 (100) | 12 (92.3) | | Positive1 beta cell autoantibodies, (%) | | | | 2 | 1 (7.7) | 2 (15.4) | | 3 | 3 (23.1) | 5 (38.5) | | 4 | 4 (30.8) | 3 (23.1) | | 5 | 4 (30.8) | 1 (7.7) | | 6 | 1 (7.7) | 2 (15.4) | | 2GADA titers, mean (SD), (min-max) (U/mL) | 916 (916), (58-2645) | 1198 (1626), (72-6006) | | Age, mean (SD) (min-max) | 9.0 (2.9), (4.6-13.8) | 9.4 (2.7), (4.6-13.0) |
|
|
1Beta cell autoantibodies: GADA, IAA, IA-2A, ZnT8RA, ZnT8QA, and ZnT8WA. 2The thresholds for GADA to be positive were . |
